FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 327:1632-1636 December 3, 1992 Number 23 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

BACKGROUND. Alglucerase (Ceredase) provides effective enzyme-replacement treatment for patients with Gaucher's disease, but at the usually recommended dose of 60 U per kilogram of body weight every two weeks (130 U per kilogram per month), it costs $382,200 per year for a 70-kg patient. Theoretical considerations suggest that more frequent administration would be more efficient. METHODS. Fourteen patients with type 1 Gaucher's disease that was moderately severe to severe were given 30 U of alglucerase per kilogram per month, in divided doses given either daily or three times weekly, or 120 U given three times weekly. The effect of the treatment on the size of the liver and spleen and on blood counts was compared with published data on patients who received a total dose four to five times as large as the lower dose we used and who received treatment every two weeks. RESULTS. The response to 30 U of alglucerase per kilogram per month, fractionated into three or seven doses weekly, was approximately the same as that reported after the administration every two weeks of a dose four or five times as large, given in the large infusions usually recommended. A fourfold increase in the dose given three times weekly, from 2.3 to 9.2 U per kilogram, did not substantially increase the rate of improvement. CONCLUSIONS. The treatment of Gaucher's disease with smaller total doses of alglucerase given more frequently yields satisfactory results. A dose of 2.3 U per kilogram three times weekly yields major financial benefits with no sacrifice of therapeutic effect. Even taking into account the increased ancillary costs of more frequent administration, this method of administering alglucerase reduces the annual cost of the drug for a 70-kg patient to about $100,000.

Source Information

Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, CA 92037.

This article has been cited by other articles:

• Enquist, I. B., Bianco, C. L., Ooka, A., Nilsson, E., Mansson, J.-E., Ehinger, M., Richter, J., Brady, R. O., Kirik, D., Karlsson, S. (2007). Murine models of acute neuronopathic Gaucher disease. Proc. Natl. Acad. Sci. USA 104: 17483-17488 [Abstract] [Full Text]  
• de Fost, M., Aerts, J. M.F.G., Groener, J. E.M., Maas, M., Akkerman, E. M., Wiersma, M. G., Hollak, C. E.M. (2007). Low frequency maintenance therapy with imiglucerase in adult type I Gaucher disease: a prospective randomized controlled trial. haematol 92: 215-221 [Abstract] [Full Text]  
• Enquist, I. B., Nilsson, E., Ooka, A., Mansson, J.-E., Olsson, K., Ehinger, M., Brady, R. O., Richter, J., Karlsson, S. (2006). Effective cell and gene therapy in a murine model of Gaucher disease. Proc. Natl. Acad. Sci. USA 103: 13819-13824 [Abstract] [Full Text]  
• de Fost, M., Hollak, C. E. M., Groener, J. E. M., Aerts, J. M. F. G., Maas, M., Poll, L. W., Wiersma, M. G., Haussinger, D., Brett, S., Brill, N., Dahl, S. v. (2006). Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis. Blood 108: 830-835 [Abstract] [Full Text]  
• Zimran, A., Elstein, D., Beutler, E. (2006). Low-dose therapy trumps high-dose therapy again in the treatment of Gaucher disease. Blood 108: 802-803 [Full Text]  
• Mankin, H. J., Rosenthal, D. I., Xavier, R. (2001). Gaucher Disease : New Approaches to an Ancient Disease. JBJS 83: 748-763 [Full Text]  
• Ponce, E., Moskovitz, J., Grabowski, G. (1997). Enzyme Therapy in Gaucher Disease Type 1: Effect of Neutralizing Antibodies to Acid beta -Glucosidase. Blood 90: 43-48 [Abstract] [Full Text]  
• Goetz, C. G., Penn, R. D., Klawans, H. L., Van Gilder, J. E., Fung, C. H.K., Lo, J. W., Spencer, D. D., Marek, K. L., Redmond, D. E., Freed, C. R., Breeze, R. E., Rosenberg, N. L., Garry, D. J., Caplan, A. L. (1993). Fetal-Tissue Transplantation for Parkinson's Disease. NEJM 329: 1498-1500 [Full Text]  
• Moscicki, R. A., Taunton-Rigby, A., Barton, N. W., Brady, R. O., Dambrosia, J. M., Grabowski, G. A., Hollak, C. E.M., Aerts, J.M.F.G., van Oers, M.H.J., Sidransky, E., Martin, B., Ginns, E. I., Freiwald, D. R., Lexchin, J., Beutler, E., Figueroa, M., Koziol, J., Garber, A. M. (1993). Treatment of Gaucher's Disease. NEJM 328: 1564-1568 [Full Text]